Cheng Cui

Dr. Cheng Cui

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2020 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
CCCheng Cui
Cheng Cui
JSJie En Valerie Sia
Jie En Valerie Sia
STSiqi Tu
Siqi Tu
XLXiaobei Li
Xiaobei Li
ZDZhongqi Dong
Zhongqi Dong
DLDongyang Liu
Dongyang Liu
Aims: This study aims to develop and verify a physiologically based pharmacokinetic (PBPK) population model for the Chinese geriatric population in Simcyp.Methods: Firstly, physiological information for the Chinese geriatric population was collected and later employed to develop the Chinese geriatric population model by recalibration of corresponding physiological parameters in the Chinese adult population model available in Simcyp (i.e., Chinese healthy volunteer model). Secondly, drug‐dependent parameters were collected for six drugs with different elimination pathways (i.e., metabolized by CYP1A2, CYP3A4 or renal excretion). The drug models were then developed and verified by clinical data from Chinese adults, Caucasian adults and Caucasian elderly subjects to ensure that drug‐dependent parameters are correctly inputted. Finally, the tested drug models in combination with the newly developed Chinese geriatric population model were applied to simulate drug concentration in Chinese elderly subjects. The predicted results were then compared with the observations to evaluate model prediction performance.Results: Ninety‐eight per cent of predicted AUC, 95% of predicted Cmax, and 100% of predicted CL values were within two‐fold of the observed values, indicating all drug models were properly developed. The drug models, combined with the newly developed population model, were then used to predict pharmacokinetics in Chinese elderly subjects aged 60–93. The predicted AUC, Cmax, and CL values were all within two‐fold of the observed values.Conclusion: The population model for the Chinese elderly subjects appears to adequately predict the concentration of the drug that was metabolized by CYP1A2, CYP3A4 or eliminated by renal clearance.

1 January 2020 in Dose-Response
Verified
Journal Article
Open access
PDF file
CCCheng Cui
Cheng Cui
JSJiabei Sun
Jiabei Sun
XWXueqing Wang
Xueqing Wang
ZYZhenxi Yu
Zhenxi Yu
YSYaqin Shi
Yaqin Shi
This study was performed to explore factors influencing the release of the proton pump inhibitor omeprazole from enteric-coated capsules in vitro and absorption in vivo in beagle dogs. Enteric-coated pellets with different enteric coating materials and coating levels were designed and prepared. All self-prepared formulations were characterized in vitro as well as in vivo and compared to the brand and generic commercial products. Evaluation of the corresponding release profiles suggested that coating material was the most critical factor. Enteric coating level determined the lag time before initiation of drug release, and subcoating level affected the drug release rate. Pharmacokinetic studies were performed in beagle dogs to further confirm the influence of formulation factors on drug absorption. Medium at pH 6.8 was a more biorelevant condition for in vitro drug release tests, although medium at pH 6.0 was better for discriminating release profiles of different formulations. A multiple level C in vitro/in vivo correlation was preliminarily established by which Tmax and Cmax of omeprazole formulations could be predicted with release parameters such as Tlag and T25. These results may facilitate quality evaluation and potentially improve the clinical efficacy of generic omeprazole products.

15 November 2022 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
CCCheng Cui
Cheng Cui
YQYuchen Qu
Yuchen Qu
JSJie En Valerie Sia
Jie En Valerie Sia
ZZZhu Zhu
Zhu Zhu
YWYang Wang
Yang Wang
DLDongyang Liu
Dongyang Liu

13 October 2023 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
YQYuchen Qu
Yuchen Qu
YYYunli Yu
Yunli Yu
JPJie Pan
Jie Pan
HLHaiyan Li
Haiyan Li
CCCheng Cui
Cheng Cui
DLDongyang Liu
Dongyang Liu

22 June 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
JSJie En Valerie Sia
Jie En Valerie Sia
XLXuan Lai
Xuan Lai
WMWen Yao Mak
Wen Yao Mak
XWXinyi Wu
Xinyi Wu
Fan ZhangFan Zhang
Fan Zhang
XXXiaoqiang Xiang
Xiaoqiang Xiang

12 November 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
CCCheng Cui
Cheng Cui
FCFangrui Cao
Fangrui Cao
IKIok Ian Kong
Iok Ian Kong
QWQinghe Wu
Qinghe Wu
FLFangqiong Li
Fangqiong Li
DLDongyang Liu
Dongyang Liu